Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Ensysce Biosciences, Inc. reported revenue of $5M, down 2.8% year over year. Operating margin was -202.1% and net margin -200.8%, on a free-cash-flow margin of -156.5% with capital expenditure at 2.4% of revenue. Every figure is computed directly from ENSC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $5M | -202.1% | -200.8% |
| FY2024 | $5M | -129.2% | -153.3% |
| FY2023 | $2M | -480.5% | -476.4% |
| FY2022 | $3M | -959.9% | -959.3% |
| FY2021 | $4M | -562.7% | -825.4% |
How does ENSC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.